Hormone treatment of macular degeneration
OwnerRussell Robyinventor
Life of this patent
Estimating the term…
Abstract
Compositions and/or methods are provided for treating macular degeneration and/or a degenerative ocular condition comprising administering to a human an effective amount of a hormone dilution.
Claims25
A method for treating macular degeneration comprising administering to a human an effective amount of a hormone dilution.
The method of claim 6 further comprising the amount of progesterone administered ranges from between approximately 0.5 mg to approximately 0.05 μg per dose.
A method of treating macular degeneration with a hormone dilution comprising:
- administering a dilution of progesterone, the dilution configured to be administered sublingually;
- and
- administering additional dilutions of progesterone as often as necessary to stimulate an effective response.
A method of treating a degenerative disease of the eye with a hormone dilution comprising:
- administering a dilution of progesterone, the dilution configured to be administered sublingually;
- and
- administering additional dilutions of progesterone as often as necessary to stimulate an effective response.
A method of treating macular degeneration using sublingual progesterone dilutions comprising administering the progesterone dilution once a day, the progesterone dilution comprising a sublingual tablet or solution formed of 10% progesterone.
A composition for treating macular degeneration comprising dilute progesterone in a concentration ranging from approximately 0.05 μg/ml to approximately 5 mg/ml.
A composition for treating macular degeneration comprising a concentration of progesterone selected from the group consisting of 5 mg/ml, 0.5 mg/ml, 50 μg/ml, 5 μg/ml, and 0.5 μg/ml.
Dependencies are inferred from the claim text.